Despite the fact that uncomplicated snoring affects more than 30% of the population, the medical fraternity has treated it with little seriousness. Even the potentially more serious disorder closely linked to snoring, obstructive sleep apnea (OSA), has been of significant concern amongst the medical fraternity since the 1980s. On the basis of the gradual realisation of the long-term destructive effects of OSA and snoring on health, an entire industry has developed to the point where the treatment of these sleep disorders is now a multi-billion dollar business. Some industry members have grown from humble beginnings to large profitable global enterprises due to the demand of Constant Positive Airway Pressure (CPAP) devices and associated accessories. However, not all OSA patients benefit from CPAP therapy. Some estimates put overall long-term compliance rates as low as 30%. The reasons for non-compliance are many and varied. This subsequently opens a market for an innovative manufacturer who can devise a solution to address these treatment objections. We believe that the SomnoDent® MAS occupies this important place in the market of OSA treatments.